Salamanca Tech organises a conference to introduce the innovative biotech ecosystem to Pharmacy and Biotechnology students

The aim of the next Salamanca Tech conference "Biotechnology and entrepreneurship: Cultivating innovative ecosystems with spin-offs" is to introduce students to the innovative and entrepreneurial ecosystems in the field of biotechnology and pharmaceuticals. The idea is, therefore, to highlight the potential of Salamanca within the biomedical field, where young people can find attractive job opportunities.

The event will be held at 11:00 am on 21 February at the Faculty of Pharmacy of the University of Salamanca. With the collaboration of the Salamanca City Council, the University offers students the opportunity to hear the testimonies of some of the entrepreneurial initiatives in the sector, and to approach the world of research from different perspectives. Anyone interested can register through this link.

The conference will focus on a roundtable discussion with the participation of Ricardo Jara, CEO and one of the founders of Immunostep; Antonio Muro, Professor of Parasitology; and Luis García Ortiz, Director of IBSAL. The meeting will be moderated by Miguel Ángel Ávila, CEO of Neurofix.

Boosting the biotech ecosystem  

Immunostep is a technology-based spin-off which emerged at the University of Salamanca. It is dedicated to the design of clinical and research products for the monitoring and treatment of diseases. Based at the University, it played a leading role in the COVID-19 pandemic with its antibody detection tests. It is an example of wealth and job creation in Salamanca, as more than 80% of its staff come from the academic institution. 

Antonio Muro, Professor of Parasitology, former Director of the Centre for Tropical Diseases and former Dean of the Faculty of Pharmacy in Salamanca, is well versed in the methods of diagnosis of infectious diseases, but also in the creation of the latest generation of RNA vaccines against a wide range of parasites.  

Luis García Ortiz, Director of IBSAL (Biomedical Research Institute of Salamanca), will also be at the table and will share his knowledge of the many different projects on which Salamanca's biomedical researchers are working.

The roundtable will be moderated by Miguel Ángel Ávila, CEO of Neurofix, a biotech company based in the Science Park of the University of Salamanca that has achieved a major milestone by reaching an agreement to develop NFX88, the pioneering drug it has been developing since 2015 to treat neuropathic pain in patients with spinal cord injury. This operation is one of the most important in the history of this sector in Castilla y León. 

The students will be able to learn about the perspectives of the four specialists and their vision of the sector, as well as of the opportunities within this growing ecosystem in Salamanca.